Market Newsdesk

Group Business Leaders Established; Functional Leaders Responsibilities Enhanced

Ashis Bhattacharya to Retire

EDEN PRAIRIE, Minn., Aug. 11, 2025 (GLOBE NEWSWIRE) — Winnebago Industries, Inc. (NYSE: WGO) today announced several key changes to its executive leadership team, including newly created group leader roles. The announcement comes as the company continues to take strategic actions that further enhance its position as the trusted leader in the premium outdoor recreation market and drive its next phase of growth.  

“These changes are designed to help us stay agile, support future growth and leverage the strong leadership talent we have across the company,” said Winnebago Industries President and CEO, Michael Happe. “Most importantly, they’re about continuing to serve our customers, supporting our employees and delivering value to our shareholders.” 

The following strategic senior executive changes are effective September 1, 2025: 

• Marine Group: Jeff Haradine will now be SVP – Marine; President- Barletta Boats. Haradine will continue to lead the Barletta pontoon business day-to-day as its president and now provide oversight of the Chris-Craft business and work with company leadership to drive additional growth in the marine segment. Steve Heese will remain President – Chris Craft, and SVP – Power Systems and provide continued oversight to the Lithionics business. Heese will remain on the executive leadership team, reporting to Haradine. Chris-Craft is not a subsidiary of Barletta Boats and will remain its own distinct business unit within this group.  
• Motorized RV Group: Casey Tubman will now be Group President – Newmar and Winnebago Motorized, with added responsibility for corporate strategic planning. Winnebago-brand Motorhomes and Specialty Vehicles will continue to be led by its president, Chris West who remains on the executive leadership team, reporting to Tubman, and retains responsibility for leading the revitalization of the Winnebago-brand motorized business. Winnebago Motorhomes is not a subsidiary of Newmar and will remain its own distinct business unit within this group. 
• Towable RV Group: As announced last year, Don Clark will remain Group President – Towable RV Segment; President – Grand Design RV. Clark continues to oversee Grand Design Towables, the rapidly emerging Grand Design Motorhomes business, and Winnebago-brand Towables. As noted previously, Winnebago Towables is not a subsidiary of Grand Design RV and will remain its own distinct business unit within this group. 

In addition, Ashis Bhattacharya, senior vice president of advanced technology, corporate ventures and engineering services, will retire, effective October 3, 2025. Bhattacharya joined Winnebago Industries in 2016 and has been instrumental in the company’s evolution from a single brand motorhome company to a portfolio of premium outdoor recreation brands.   

“Ashis was one of the first key hires I made when coming to Winnebago Industries and since then has made a lasting, positive impact on almost every aspect of our company through his dedication to a customer-first approach,” said Happe. “I want to express my deep appreciation for his work and unwavering commitment to our mission. His legacy will be felt here for many years.”  

To ensure continuity and momentum, the following additional leadership changes will take effect September 1, 2025: 

• Steve Speich, SVP – Enterprise Operations and Product Technology, will assume responsibility for advanced technology and engineering services in addition to his manufacturing/supply chain oversight. 
• Amber Holm will become SVP – Chief Marketing and Experience Officer, leading a new customer service center of excellence in addition to her enterprise marketing responsibilities. Holm will also have the charge of building a stronger aftermarket business strategy for the enterprise.  
• Bryan Hughes will take on the role of SVP – Chief Financial Officer, Investor Relations, Information Technology and Business Development. Hughes will oversee IT and will lead the corporate venture capital program. Sri Koneru, chief information officer, will report to Bryan and remains on the ELT. He will continue to advance our critical IT infrastructure and investments.   

About


 


Winnebago Industries
 

Winnebago Industries, Inc. is a leading North American manufacturer of outdoor lifestyle products under the Winnebago, Grand Design, Chris-Craft, Newmar and Barletta brands, which are used primarily in leisure travel and outdoor recreation activities. The Company builds high-quality motorhomes, travel trailers, fifth-wheel products, outboard and sterndrive powerboats, pontoons, and commercial community outreach vehicles. Committed to advancing sustainable innovation and leveraging vertical integration in key component areas, Winnebago Industries has multiple facilities in Iowa, Indiana, Minnesota, and Florida. The Company’s common stock is listed on the New York Stock Exchange and traded under the symbol WGO. For access to Winnebago Industries’ investor relations material or to add your name to an automatic email list for Company news releases, visit http://investor.wgo.net. 

Media Contact: Katlyn Beniek  [email protected]

• Treatment of a subgroup of patients with post-acute sequelae of SARS-CoV-2.
• Forecast adds to Tevogen Bio’s Oncology therapeutic area projections of $1 billion in the launch year and $10–$14 billion over the first five years.

WARREN, N.J., Aug. 11, 2025 (GLOBE NEWSWIRE) — Tevogen Bio (“Tevogen” or “Tevogen Bio Holdings Inc.”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech developing off-the-shelf, genetically unmodified T cell therapeutics to treat infectious disease and cancers, today announced its top-line revenue forecast for its specialty care pipeline, projecting nearly $1 billion in revenue in its launch year and a cumulative 5-year estimate of between $18 billion and $22 billion. This forecast reflects the company’s unique, faster, and cost-efficient drug development model which has the potential to serve as a blueprint to ensure sustainable medical innovation for years to come.

Pipeline

• TVGN 489:
  • Treatment of SARS-CoV-2 infection in patients with B cell hematologic cancer
    [part of Tevogen Bio Oncology forecast]
  • Treatment of SARS-CoV-2 infection in patients with other cancers
    [part of Tevogen Bio Oncology forecast]
  • SARS-CoV-2 infection in patients under treatment for rheumatoid arthritis
  • SARS-CoV-2 infection in patients under treatment for and psoriatic arthritis
  • Treatment of Long COVID [part of Tevogen Bio Specialty Care forecast]
• TVGN 920: Cervical cancer prevention
• TVGN 930: EBV-associated lymphomas
• TVGN 960: Mouth and throat cancer
• TVGN 601: Multiple sclerosis

About Tevogen Bio

Tevogen is a clinical-stage specialty immunotherapy company harnessing CD8+ cytotoxic T lymphocytes, to develop off-the-shelf, genetically unmodified T cell therapeutics to treat infectious disease and cancers, aiming to address the significant unmet needs of large patient populations. Tevogen leadership believes that sustainability and commercial success in the current era of healthcare rely on ensuring patient accessibility through advanced science and innovative business models. Tevogen has reported positive safety data from its proof-of-concept clinical trial, and its key intellectual property assets are wholly owned by the company, not subject to any third-party licensing agreements. These assets include three granted patents and numerous pending patents, two of which are related to artificial intelligence.

Tevogen is driven by a team of experienced industry leaders and scientists with drug development and global product launch experience. Tevogen’s leadership believes that accessible personalized therapeutics are the next frontier of medicine, and that disruptive business models are required to sustain medical innovation.

Forward Looking Statements

This press release contains certain forward-looking statements, including without limitation statements relating to: expectations regarding the healthcare and biopharmaceutical industries; Tevogen’s development of, the potential benefits of, and patient access to its product candidates for the treatment of infectious diseases, cancer and neurological disorders, including TVGN 489 for the treatment of COVID-19 and Long COVID; Tevogen’s ability to develop additional product candidates, including through use of Tevogen’s ExacTcell platform; the anticipated benefits of ExacTcell; expectations regarding Tevogen’s future clinical trials; and Tevogen’s ability to generate revenue in the future. Forward-looking statements can sometimes be identified by words such as “may,” “could,” “would,” “expect,” “anticipate,” “possible,” “potential,” “goal,” “opportunity,” “project,” “believe,” “future,” and similar words and expressions or their opposites. These statements are based on management’s expectations, assumptions, estimates, projections and beliefs as of the date of this press release and are subject to a number of factors that involve known and unknown risks, delays, uncertainties and other factors not under the company’s control that may cause actual results, performance or achievements of the company to be materially different from the results, performance or other expectations expressed or implied by these forward-looking statements.

Factors that could cause actual results, performance, or achievements to differ from those expressed or implied by forward-looking statements include, but are not limited to: that Tevogen will need to raise additional capital to execute its business plan, which may not be available on acceptable terms or at all; the effect of the recent business combination with Semper Paratus Acquisition Corporation (the “Business Combination”) on Tevogen’s business relationships, operating results, and business generally; the outcome of any legal proceedings that may be instituted against Tevogen; changes in the markets in which Tevogen competes, including with respect to its competitive landscape, technology evolution, or regulatory changes; changes in domestic and global general economic conditions; the risk that Tevogen may not be able to execute its growth strategies or may experience difficulties in managing its growth and expanding operations; the risk that Tevogen may not be able to develop and maintain effective internal controls; costs related to the Business Combination and the failure to realize anticipated benefits of the Business Combination; the failure to achieve Tevogen’s commercialization and development plans and identify and realize additional opportunities, which may be affected by, among other things, competition, the ability of Tevogen to grow and manage growth economically and hire and retain key employees; the risk that Tevogen may fail to keep pace with rapid technological developments to provide new and innovative products and services or make substantial investments in unsuccessful new products and services; the ability to develop, license or acquire new therapeutics; that Tevogen will need to raise additional capital to execute its business plan, which may not be available on acceptable terms or at all; the risk of regulatory lawsuits or proceedings relating to Tevogen’s business; uncertainties inherent in the execution, cost, and completion of preclinical studies and clinical trials; risks related to regulatory review, approval and commercial development; risks associated with intellectual property protection; Tevogen’s limited operating history; and those factors discussed or incorporated by reference in Tevogen’s Annual Report on Form 10-K and subsequent filings with the SEC.

You should not place undue reliance on forward-looking statements, which speak only as of the date they are made. Tevogen undertakes no obligation to update any forward-looking statements, except as required by applicable law.

Contacts

Tevogen Bio Communications
T: 1 877 TEVOGEN, Ext 701
[email protected]

DARIEN, Conn., Aug. 11, 2025 (GLOBE NEWSWIRE) — Carronade Capital Management, LP on behalf of its managed entities (“Carronade Capital”, “our” or “we”), which beneficially own approximately 3.2 million shares of Common Stock of Cannae Holdings, Inc. (NYSE: CNNE) (“Cannae” or the “Company”) and is one of the Company’s top shareholders, today posed important questions that it believes shareholders would like to see answered by Cannae’s executive team during its second quarter 2025 earnings call scheduled for 5:00 pm ET on August 11, 2025.

As a top shareholder, we are disappointed by the lack of transparency, responsiveness and engagement we have seen from Cannae and its Board of Directors (the “Board”). Cannae’s absolute and relative TSR from inception up until our engagement were -5% and -156%, respectively. Since our public engagement on March 20, 2025, absolute and relative TSR have improved to +18% and +16%, respectively, as we believe the market is endorsing Carronade’s approach and the Company has begun to buy back a small amount of stock.¹ However, the Board has repeatedly failed to address key governance and strategic issues, instead opting to take steps to further entrench itself and disenfranchise shareholders as evidenced by generous compensation packages for management and the Board and delaying the 2025 Annual Meeting of Shareholders. We urge our fellow shareholders and Company analysts to hold Cannae accountable and demand clear, specific answers to the following questions during today’s call:

• When will Cannae hold its 2025 Annual Meeting of Shareholders? How does the Board justify further delay given it’s been nearly 14 months since its last Annual Meeting without any indication of intent to hold the meeting anytime in the near future?
• Elaborate on Bill Foley’s responsibilities under his new Director Services Agreement now that he has triggered his payout package gifted by the Board in March of this year? How does the new Board construction, with one of Bill Foley’s long-time associates as Chairman and two new directors that were added during the midst of a proxy contest, give shareholders confidence that their best interests are represented in the boardroom when the incumbent directors have consistently received negative recommendations from leading shareholder advisory services?
• What is the timeline for returning the proceeds from the Dun & Bradstreet sale and how much will shareholders receive? In March, Cannae committed to returning at least $300 million of the proceeds via share repurchases and has since completed approximately one-third of the buyback. Will the remaining $200 million be returned directly to non-insider shareholders, or will a portion be held back to repurchase half of Bill Foley’s shares at a 20% premium to the market price pursuant to his new Director Services Agreement? If so, will Cannae commit to offering shareholders the same premium in a tender offer?
• What is the plan for monetizing and returning other public investments that have destroyed significant amounts of shareholder capital?

Shareholders deserve answers. Carronade Capital remains committed in its efforts to effect meaningful change to drive shareholder value at Cannae and will continue to seek shareholder representation on the Board at the 2025 Annual Meeting. Carronade’s four highly qualified and independent nominees are Mona Aboelnaga, Benjamin Duster, Dennis Prieto and Cherie Schaible.

_______________
¹ Bloomberg as of August 8, 2025. Relative to updated Peer Group disclosed in 2024 10-K: Main Street Capital, Compass Diversified Holdings, StepStone Group, Hercules Capital, Federated Hermes, Capital Southwest, Artisan Partners Asset Management, Trinity Capital, Hamilton Lane, Bridge Investment Group and GCM Grosvenor.

About Carronade Capital

Carronade Capital Management, LP (“Carronade Capital Management”) is a multi-strategy investment firm based in Darien, Connecticut with approximately $2.5 billion in assets under management that focuses on process driven investments in catalyst-rich situations. Carronade Capital Management, founded in 2019 by industry veteran Dan Gropper, currently employs 14 team members. Carronade Capital was launched on July 1, 2020. Dan Gropper brings with him nearly three decades of special situations credit experience serving in senior roles at distinguished investment firms, including Elliott Management Corporation, Fortress Investment Group and Aurelius Capital Management, LP.

Media Contact:

Paul Caminiti / Jacqueline Zuhse
Reevemark
(212) 433-4600
[email protected]

Investor Contacts:

Andy Taylor / Win Rollins
Carronade Capital Management, LP
(203) 485-0880
[email protected]

Pat McHugh
Okapi Partners LLC
(212) 297-0720
[email protected]

Disclaimers

This press release does not constitute an offer to sell or a solicitation of an offer to buy any of the securities described herein in any state to any person. This press release does not recommend the purchase or sale of a security. There is no assurance or guarantee with respect to the prices at which any securities of Cannae Holdings, Inc. (the “Company”) will trade, and such securities may not trade at prices that may be implied herein. In addition, this press release and the discussions and opinions herein are for general information only, and are not intended to provide financial, legal or investment advice. Each shareholder of the Company should independently evaluate the proxy materials and make a decision that aligns with their own financial interests, consulting with their own advisers, as necessary.

This press release contains forward-looking statements. Forward-looking statements are statements that are not historical facts and may include projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions and expectations with respect to future financial results, events, operations, services, product development and potential, and statements regarding future performance. Forward-looking statements are generally identified by the words “expects”, “anticipates”, “believes”, “intends”, “estimates”, “plans”, “will be” and similar expressions. Although Carronade Capital and its affiliates believe that the expectations reflected in forward-looking statements contained herein are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties—many of which are difficult to predict and are generally beyond the control of Carronade or the Company—that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. In addition, the foregoing considerations and any other publicly stated risks and uncertainties should be read in conjunction with the risks and cautionary statements discussed or identified in the Company’s public filings with the U.S. Securities and Exchange Commission, including those listed under “Risk Factors” in the Company’s annual reports on Form 10-K and quarterly reports on Form 10-Q . The forward-looking statements speak only as of the date hereof and, other than as required by applicable law, Carronade does not undertake any obligation to update or revise any forward-looking information or statements. Certain information included in this press release is based on data obtained from sources considered to be reliable. Any analyses provided herein is intended to assist the reader in evaluating the matters described herein and may be based on subjective assessments and assumptions and may use one among alternative methodologies that produce different results. Accordingly, any analyses should not be viewed as factual and should not be relied upon as an accurate prediction of future results. All figures are estimates and, unless required by law, are subject to revision without notice.

Certain of the funds(s) and/or account(s) (“Accounts”) managed by Carronade Capital Management, LP (“Carronade Capital Management”) currently beneficially own shares of the Company. Carronade Capital Management in the business of trading (i.e., buying and selling) securities and intends to continue trading in the securities of the Company. You should assume the Accounts will from time to time sell all or a portion of its holdings of the Company in open market transactions or otherwise, buy additional shares (in open market or privately negotiated transactions or otherwise), or trade in options, puts, calls, swaps or other derivative instruments relating to such shares. Consequently, Carronade Capital Management’s beneficial ownership of shares of, and/or economic interest in, the Company may vary over time depending on various factors, with or without regard to Carronade Capital Management’s views of the Company’s business, prospects, or valuation (including the market price of the Company’s shares), including, without limitation, other investment opportunities available to Carronade Capital Management, concentration of positions in the portfolios managed by Carronade Capital Management, conditions in the securities markets, and general economic and industry conditions. Without limiting the generality of the foregoing, in the event of a change in the Company’s share price on or following the date hereof, Carronade Capital Management may buy additional shares or sell all or a portion of its Account’s holdings of the Company (including, in each case, by trading in options, puts, calls, swaps, or other derivative instruments relating to the Company’s shares). Carronade Capital Management also reserves the right to change the opinions expressed herein and its intentions with respect to its investment in the Company, and to take any actions with respect to its investment in the Company as it may deem appropriate, and disclaims any obligation to notify the market or any other party of any such changes or actions, except as required by law.

Certain Information Concerning the Participants

Carronade Capital Master, LP (“Carronade”), together with the other participants named herein (collectively, “Carronade Capital”), has filed a preliminary proxy statement and accompanying GOLD proxy card with the Securities and Exchange Commission (“SEC”) to be used to solicit votes for the election of Carronade Capital’s highly-qualified director nominees at the 2025 annual meeting of shareholders of the Company.

CARRONADE CAPITAL STRONGLY ADVISES ALL STOCKHOLDERS OF THE COMPANY TO READ THE PROXY STATEMENT AND OTHER PROXY MATERIALS AS THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION. SUCH PROXY MATERIALS WILL BE AVAILABLE AT NO CHARGE ON THE SEC’S WEB SITE AT HTTP://WWW.SEC.GOV. IN ADDITION, THE PARTICIPANTS IN THIS PROXY SOLICITATION WILL PROVIDE COPIES OF THE PROXY STATEMENT WITHOUT CHARGE, WHEN AVAILABLE, UPON REQUEST. REQUESTS FOR COPIES SHOULD BE DIRECTED TO THE PARTICIPANTS’ PROXY SOLICITOR.

The participants in the proxy solicitation are anticipated to be Carronade, Carronade Capital GP, LLC (“Carronade Capital GP”), Carronade Capital Management, Carronade Capital Management GP, LLC (“Carronade Capital Management GP”), Dan Gropper, Mona Aboelnaga, Benjamin C. Duster, IV, Dennis A. Prieto and Chérie L. Schaible.

As of the date hereof, Carronade beneficially owns directly 3,012,218 shares of Common Stock, par value $0.0001 per share, of the Company (the “Common Stock”). Carronade Capital GP, as the general partner of Carronade, may be deemed the beneficial owner of the 3,012,218 shares of Common Stock owned by Carronade. As of the date hereof, 176,809 shares of Common Stock were held in a certain account managed by Carronade Capital Management (the “Managed Account”). Carronade Capital Management, as the investment manager of Carronade, may be deemed the beneficial owner of an aggregate of 3,189,027 shares of Common Stock directly owned by Carronade and held in the Managed Account. Carronade Capital Management GP, as the general partner of Carronade Capital Management, may be deemed the beneficial owner of an aggregate of 3,189,027 shares of Common Stock directly owned by Carronade and held in the Managed Account. As the Managing Member of Carronade Capital Management GP, Mr. Gropper may be deemed the beneficial owner of an aggregate of 3,189,027 shares of Common Stock directly owned by Carronade and held in the Managed Account. As of the date hereof, Ms. Aboelnaga directly beneficially owns 1,400 shares of Common Stock. As of the date hereof, Mr. Duster directly beneficially owns 1,338.329 shares of Common Stock. As of the date hereof, Mr. Prieto directly beneficially owns 1,470 shares of Common Stock. As of the date hereof, Ms. Schaible directly beneficially owns 1,360 shares of Common Stock.

ATLANTA, Aug. 11, 2025 (GLOBE NEWSWIRE) — Holzer & Holzer, LLC is investigating whether Simulations Plus, Inc. (“Simulations Plus” or the “Company”) (NASDAQ: SLP) complied with federal securities laws. On July 14, 2025, Simulations Plus reported financial results for its third quarter fiscal 2025. The Company noted that it had recognized a one-time non-cash impairment charge of $77.2 million for the quarter, and that it had “implemented a strategic reorganization, transitioning from a business unit structure to a functionally-driven operating model.” Following this news, the price of the Company’s stock dropped. 

If you purchased Simulations Plus stock and suffered a loss on that investment, you are encouraged to contact Corey Holzer, Esq. at [email protected] or Joshua Karr, Esq. at [email protected], call our toll-free number at (888) 508-6832, or visit our website at www.holzerlaw.com/case/simulations-plus/ to discuss your legal rights.  

Holzer & Holzer, LLC, an ISS top rated securities litigation law firm for 2021, 2022, and 2023, dedicates its practice to vigorous representation of shareholders and investors in litigation nationwide, including shareholder class action and derivative litigation. Since its founding in 2000, Holzer & Holzer attorneys have played critical roles in recovering hundreds of millions of dollars for shareholders victimized by fraud and other corporate misconduct. More information about the firm is available through its website, www.holzerlaw.com, and upon request from the firm. Holzer & Holzer, LLC has paid for the dissemination of this promotional communication, and Corey Holzer is the attorney responsible for its content.  
  
CONTACT:  
Corey Holzer, Esq.
(888) 508-6832 (toll-free)
[email protected]

• This renewal ensures the continuity of the longest-standing alliance in the country, which enables the redemption of around 2 million tickets per year on average.
• This milestone drives the alliance to continue innovating in its product value proposition, reaffirming the commitment to continuously enhance the travel experience of the program’s members.

SANTIAGO, Chile, Aug. 11, 2025 (GLOBE NEWSWIRE) — Banco Santander Chile (NYSE: BSAC; SSE: Bsantander) and LATAM Airlines Group S.A. (NYSE: LTM; SSE: LTM) have renewed their strategic alliance for another five years, consolidating over three decades of collaboration. This partnership has enabled the development of the most recognized loyalty program in the Chilean market, connecting millions of people with travel-related benefits and LATAM Pass program services.

Over the past 30 years, the alliance has consistently received high customer appreciation. To illustrate the scale of the partnership, an average of around 2 million airline tickets are redeemed each year through miles accumulated via the bank’s products. This is equivalent to operating 3,415 A320 aircraft exclusively with alliance passengers. In addition, alliance members have enjoyed an enhanced flying experience thanks to the benefits offered by the affiliated credit cards.

Andrés Trautmann, Country Head of Banco Santander Chile, stated: “With more than 30 years of history, this alliance has become a cornerstone of our daily relationship with customers. Its renewal is a strategic decision aimed at strengthening and projecting into the future a value proposition that has proven to be relevant and widely appreciated by those who place their trust in us.”

“We are thrilled to renew this alliance with Banco Santander, a strategic partner for LATAM Pass, with whom we aim to continue creating value for customers. This milestone continues a historic relationship and reaffirms our commitment to elevating the travel experience of every one of our members. At LATAM Pass, we will continue working to offer unique benefits and unforgettable experiences through the region’s leading loyalty program,” said Roberto Alvo, CEO of the LATAM Group.

Currently, the LATAM Pass program has over 51 million members worldwide and has grown by 40% since 2019, making it the fourth-largest loyalty program in the Americas and the seventh-largest globally.

Meanwhile, the Santander LATAM Pass alliance currently has more than 688,000 customers, making it the most established, valued, and important loyalty program in Chile.

Photo caption (from left to right):

Cristian Ortiz, CEO of LATAM Pass; Roberto Alvo, CEO of the LATAM Group; Andrés Trautmann, CEO of Banco Santander Chile; and Ángel García, Payments Manager.

About Banco Santander Chile


Banco Santander Chile is one of the companies with the highest risk ratings in Latin America, with an A2 rating from Moody’s, A- from Standard & Poor’s, A+ from the Japan Credit Rating Agency, AA- from HR Ratings, and A from KBRA. All of our ratings have a stable outlook as of the date of this report.

As of June 30, 2025, the bank had total assets of Ch$66,188,442 million (US$69,371 million), total gross loans (including those owed by banks) at amortized cost of Ch$40,942,542 million (US$42,911 million), total deposits of Ch$29,614,613 million (US$31,039 million), and shareholders’ equity was $4,514,322 million (US$4,731 million). The BIS capital ratio was 17.0%, with a core capital ratio of 10.9%. As of June 30, 2025, Santander Chile employed 8,660 people and had 231 branches throughout Chile.

About The LATAM Pass loyalty program


The LATAM Pass loyalty program allows its members to earn miles by flying, using credit cards, and interacting with participating merchants. These miles can then be redeemed for flights and products available on the LATAM Pass Shopping platform. Members can also access exclusive benefits—depending on their tier—to enhance their onboard experience. The list of participating merchants can be found on the program’s website.

CONTACT INFORMATION

Cristian Vicuña
Chief Strategy Officer and Head of Investor Relations
Banco Santander Chile
Bandera 140, 20^th Floor
Santiago, Chile
Email: [email protected]
Website: www.ir.santander.cl

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/8be95e72-9da6-4a60-9c72-300ae95ad1e4